Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.00    2.00 (3.23%)
Bid:
63.00
Ask:
65.00
Spread: 2.00 (3.175%)
Market Cap: £15.59m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

11 Feb 2022 07:00

RNS Number : 4135B
MyCelx Technologies Corporation
11 February 2022
 

11 February 2022

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Trading Update

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, is pleased to announce a trading update on the Company's operations.

 

Highlights

 

· Anticipated unaudited 2021 revenue of ca.$8.5 million (2020: $7.1 million)

 

· As at 31 December 2021, the Company had cash and cash equivalents, including restricted cash, of $3.2 million (2021 H1: $5.5 million), and the Company continues to manage its working capital and support growth

· Operations continue to perform in line with expectations, with minimal to no impact of Covid-19 in MYCELX's day-to-day business functions

 

· In 2022 the Company is targeting a similar level of year-on-year revenue growth but this remains subject to the timing of anticipated contract wins and renewals

 

Commenting on these results, Connie Mixon, CEO, said:

 

"We are very pleased with how the Company performed in the second half of 2021 and based on the start of the year, we are targeting to deliver year-on-year growth to our stakeholders in 2022. Oil prices are at their highest levels since 2014, which we anticipate will lead to greater levels of production activity across the regions in which we operate and will likely lead to heightened demand for our environmental solutions in these areas.

 

We were pleased to report a successful outcome at our PFAS trial in the United States in December, as we believe the PFAS remediation market has the potential to generate substantial cash flows for the business for the foreseeable future.

 

Finally, we continue to successfully navigate the Covid-19 pandemic, with the Company now experiencing little to no impact on its day-to-day operations. However, we continue to take all precautions necessary in order to safeguard the welfare of our workforce."

 

 

For further information, please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

Tel: +1 888 306 6843

 

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor

Gordon Hamilton

 

 

Tel: +44 20 7523 8150

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFDSMFEESEFE
Date   Source Headline
14th May 20217:00 amRNSPFAS System Validation
13th Apr 20211:49 pmRNSGrant of Options
23rd Mar 20217:00 amRNSBoard Changes
17th Mar 20213:37 pmRNSHolding(s) in Company
17th Mar 20212:35 pmRNSHolding(s) in Company
15th Mar 20217:00 amRNSHolding(s) in Company
2nd Mar 20217:00 amRNSTrading Update
18th Feb 20217:00 amRNSSale of MYCELX property in Duluth, USA
17th Feb 20214:32 pmRNSHolding(s) in Company
5th Jan 20212:32 pmRNSHolding(s) in Company
4th Jan 20217:00 amRNSHolding(s) in Company
27th Oct 20202:55 pmRNSResult of Annual Meeting
2nd Oct 20202:56 pmRNSNotice of Annual Meeting
22nd Sep 20207:00 amRNSHalf Year Results Statement
4th Sep 20207:00 amRNSAppointment of Nominated Adviser and Sole Broker
7th Aug 202011:50 amRNSDirector/PDMR Shareholding
22nd Jun 20207:00 amRNSContract extension with SABIC
19th Jun 20207:00 amRNSAnnual Financial Report
27th May 20207:00 amRNSFinal Results for the year ending 31 December 2019
11th May 20207:00 amRNSNew Project Award
14th Apr 20207:00 amRNSTrading Update
9th Mar 20207:00 amRNSClosure of Restricted Stock Line
5th Mar 20207:00 amRNSTrading Update
13th Dec 201910:25 amRNSBlock listing Interim Review
4th Nov 20197:00 amRNSTrading Update
16th Sep 20197:00 amRNSHalf Year Results Statement
20th Aug 201912:42 pmRNSHolding(s) in Company
16th Aug 20193:02 pmRNSDirector Shareholding
29th Jul 20197:00 amRNSDirectorate Changes
26th Jul 20197:00 amRNSAppointment of Nominated Adviser & Broker
22nd Jul 20191:34 pmRNSHolding(s) in Company
10th Jul 201912:57 pmRNSResult of Annual Meeting
14th Jun 20197:00 amRNSTrading Update
11th Jun 20197:00 amRNSBlock listing Interim Review
6th Jun 20197:00 amRNSIssue of Equity
31st May 20191:57 pmRNSAnnual Financial Report
13th May 20197:00 amRNSFinal Results for the year ending 31 December 2018
28th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
15th Mar 20197:00 amRNSHolding(s) in Company
13th Mar 20197:00 amRNSIssue of Equity
28th Feb 20194:54 pmRNSResults of Fundraising
28th Feb 20197:00 amRNSProposed $1.8 million Placing
13th Feb 201910:22 amRNSTrading Update
21st Dec 20187:00 amRNSHolding(s) in Company
11th Dec 20187:15 amRNSDirectorate Changes
7th Dec 20187:00 amRNSBlock Admission Interim Update
29th Nov 20187:00 amRNSNew Project Award and Trading Update
8th Oct 20187:00 amRNSNew Project Award and Trading Update
12th Sep 20187:00 amRNSHalf Year Results Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.